NxStage Medical, Inc. (NXTM) saw its loss narrow to $1.19 million, or $0.02 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $1.28 million, or $0.02 a share.

Revenue during the quarter grew 8.54 percent to $96.83 million from $89.21 million in the previous year period. Gross margin for the quarter expanded 160 basis points over the previous year period to 42.54 percent. Operating margin for the quarter stood at negative 1.74 percent as compared to a negative 1.09 percent for the previous year period.

Operating loss for the quarter was $1.68 million, compared with an operating loss of $0.98 million in the previous year period.

"We believe we are well positioned with tremendous growth opportunities. We continue to execute at a high level and advance our product pipeline at an impressive pace," stated Jeffrey H. Burbank, Founder and chief executive officer of NxStage. "I believe that we have one of the most exciting product pipelines in the industry. Our primary objective is to deliver innovative solutions that have the potential to give ESRD patients the ability to live longer and fuller lives while on dialysis. We don't underestimate the hard work it will take to bring these innovations to market, but we remain confident in our capabilities. We believe our products and track record speak for themselves."

For financial year 2017, NxStage Medical, Inc. expects revenue to be in the range of $400 million to $405 million.

For the second-quarter 2017, NxStage Medical, Inc. expects revenue to be in the range of $95 million to $97 million. The company forecasts net loss to be in the range of $1 million to $3 million.